Why the study?
While SGLT2 inhibitors reduce mortality and morbidity in chronic HF, their clinical implications in acute decompensated HF remain uncertain.
Does continuing SGLT2 inhibitor therapy at discharge reduce heart failure re-hospitalization in T2DM patients hospitalized for acute decompensated heart failure?
Does continuing SGLT2 inhibitor therapy at discharge reduce heart failure re-hospitalization in T2DM patients hospitalized for acute decompensated heart failure?
Answers are grounded in this paper and cite their sources.
Continuing SGLT2 inhibitor therapy at discharge in T2DM patients hospitalized for acute decompensated heart failure significantly reduces the risk of unplanned heart failure re-hospitalization.
Sodium-glucose cotransporter 2 inhibitor (SGLT2i) reduces mortality and morbidity in patients with chronic heart failure (HF). However, the clinical implication of SGLT2i therapy in patients with acute decompensated HF remains uncertain. We prospectively studied 86 type 2 diabetic mellitus (T2DM) patients (71.8 ± 12.1 years, 55 men) who were hospitalized for acute decompensated HF and received SGLT2i during the index hospitalization. Among the patients, 56 continued SGLT2i at discharge and 30 did not. The continued group experienced fewer HF re-hospitalizations than the discontinued group (24% versus 39%, P = 0.008) with a hazard ratio of 0.29 (95% confidence interval 0.10-0.85) adjusted for other significant potential confounders. In conclusion, long-term SGLT2i therapy might prevent unplanned HF re-hospitalization in patients with T2DM and acute decompensated HF.
No takes yet. Share an insight, caveat, or question.
Nakagaito et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: